Dapagliflozin (Dafoxa) for Heart Failure
Dapagliflozin is strongly recommended for adults with chronic heart failure with reduced ejection fraction (HFrEF, LVEF ≤40%), with or without diabetes, and should be initiated at 10 mg daily to reduce heart failure hospitalizations and cardiovascular mortality. 1
Heart Failure with Reduced Ejection Fraction (LVEF ≤40%)
The evidence for dapagliflozin in HFrEF is unequivocal and represents the highest quality data available. The 2021 Canadian Cardiovascular Society/Canadian Heart Failure Society guidelines provide a Strong Recommendation with High-Quality Evidence for SGLT2 inhibitors (specifically dapagliflozin or empagliflozin) in patients with HFrEF, regardless of diabetes status 1. This recommendation is based on landmark trials showing:
- 26% reduction in the composite of cardiovascular death or worsening heart failure 1
- 30% reduction in heart failure hospitalizations 1
- 18% reduction in cardiovascular death 1
- Benefits observed as early as 30 days after initiation 1
The benefits are consistent across all subgroups, including patients already on optimal guideline-directed medical therapy (ACE inhibitors/ARBs, beta-blockers, mineralocorticoid receptor antagonists, and even sacubitril-valsartan) 1, 2.
Dosing for HFrEF
- Starting dose: 10 mg once daily 3
- Target dose: 10 mg once daily (no titration needed) 3
- Can be initiated early in the disease course, even during hospitalization for stabilized patients 2
Heart Failure with Mildly Reduced or Preserved Ejection Fraction (LVEF >40%)
For patients with LVEF >40%, dapagliflozin is also recommended based on the 2025 Canadian guidelines and recent trial data. The DELIVER trial demonstrated that dapagliflozin 10 mg daily reduced the composite of worsening heart failure or cardiovascular death by 18% (HR 0.82,95% CI 0.73-0.92) in patients with LVEF >40% 3, 4. The 2022 AHA/ACC/HFSA guidelines give empagliflozin (a similar SGLT2 inhibitor) a Class 2a recommendation for HFpEF, with the benefit being greater in patients with LVEF closer to 50% 5.
The 2025 Canadian guidelines specifically recommend dapagliflozin 10 mg daily for HFnrEF (LVEF >40%) 3, with benefits observed across the entire spectrum including those with LVEF ≥50% 4.
Renal Function Considerations
Dapagliflozin can be initiated in patients with eGFR ≥20 mL/min/1.73 m² based on updated 2022 guidance 6. Key points:
- eGFR ≥20 mL/min/1.73 m²: Safe to initiate 1, 6
- eGFR <30 mL/min/1.73 m²: Original trials excluded these patients, but newer data supports use down to eGFR 20 1, 6
- Temporary eGFR decline of up to 15% may occur in the first 1-3 months but typically resolves and does not require discontinuation 1
- Continue therapy even if eGFR falls below initiation threshold unless patient is not tolerating treatment or requires dialysis 6
Diabetes Status
Dapagliflozin is effective regardless of diabetes status. In the DAPA-HF trial, 58% of participants did not have diabetes, and the benefit was nearly identical in both groups (HR 0.73 in non-diabetics vs 0.75 in diabetics) 7. This represents a paradigm shift—SGLT2 inhibitors are now heart failure medications, not just diabetes drugs.
Safety Profile and Monitoring
Common adverse effects are manageable and rarely require discontinuation:
- Genital mycotic infections (10-15% in women, lower in men): Treat with antifungals, rarely requires drug discontinuation 1
- Volume depletion: Monitor for hypovolemia; consider proactive diuretic dose reduction in high-risk patients 6
- Hypoglycemia: Only if combined with insulin or sulfonylureas—adjust these medications proactively 6
- Diabetic ketoacidosis: Rare; institute sick day protocol (hold during acute illness) 6
- No excess risk of symptomatic hypotension, acute kidney injury, or amputations in heart failure trials 1
Contraindications
Practical Implementation
Start dapagliflozin early—do not wait for "optimization" of other therapies. The 2021 Canadian guidelines explicitly state it is reasonable to start SGLT2 inhibitors early in the disease course 1. Benefits are additive to other guideline-directed medical therapy, and early initiation (even during hospitalization for stabilized patients) prevents the common problem where deferred initiation leads to never starting the medication 2.
For hospitalized patients who are stabilized or pre-discharge: Dapagliflozin is particularly well-suited for in-hospital initiation due to minimal blood pressure effects, no excess renal adverse events, and rapid clinical benefit within days to weeks 2.
Special Populations
Severe heart failure (NYHA III/IV): Dapagliflozin remains effective and safe even in patients with severe symptoms, recent hospitalization, and poor quality of life scores 9. The relative benefit is consistent regardless of disease severity.
Older patients: Real-world data confirms effectiveness in older populations with multiple comorbidities who were often excluded from trials 10. However, monitor renal function more closely in older patients, as they may experience greater eGFR decline 10.
Critical Pitfall to Avoid
Do not discontinue dapagliflozin during temporary eGFR decline. A reversible dip in eGFR is expected and represents hemodynamic adjustment, not kidney injury. The drug actually preserves long-term kidney function and prevents progression to dialysis 1, 6, 1.